| Literature DB >> 33986837 |
Roxana Popescu1,2, Marioara Nicoleta Filimon2,3, Daliborca Cristina Vlad1, Doina Verdes1,2, Aurica Moatar1, Georgiana Moise1, Kristine Guran1, Ion Valeriu Caraba4, Liliana Petculescu Ciochina4, Iulia Pinzaru5, Cristina Adriana Dehelean5, Gabi Dumitrescu2,4.
Abstract
Ionic liquids (ILs) exhibit cytotoxic effects on prokaryotic and eukaryotic cells. In this study, the antibacterial and antiproliferative activities of tetrahexylammonium bromide-based ILs were investigated. In order to evaluate the therapeutic potential of these ionic liquids, firstly microbiological assay using both Gram-positive and Gram-negative bacteria were conducted by employing Disk-Diffusion and 2,3,5-triphenyltetrazolium chlorine (TTC) methods to assess the antimicrobial effects. Likewise, the antitumor effects on 2D and 3D cell culture systems were assessed using the human colon cancer Caco-2 cell line and cytotoxic activity was assessed using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and Alamar blue assays. Results obtained showed that [CH3(CH2)5]4N(Br) possesses an antibacterial potential, particularly in the case of two bacteria, S. aureus (Gram+) and H. influenzae (Gram-). Preliminary screening of antiproliferative activity showed moderate activity, except for the concentration of 10 mM. Furthermore, regarding the effect of [CH3(CH2)5]4N(Br) on tumor cell aggregation, positive outcomes were noted. [CH3(CH2)5]4N(Br) presents promising and under-explored potential to improve antibacterial or anticancer therapies. Copyright: © Popescu et al.Entities:
Keywords: antibacterial; antiproliferative; ionic liquids; tetrahexylammonium bromide-based ionic liquid
Year: 2021 PMID: 33986837 PMCID: PMC8112146 DOI: 10.3892/etm.2021.10104
Source DB: PubMed Journal: Exp Ther Med ISSN: 1792-0981 Impact factor: 2.447
Figure 1The diameter of the zone of inhibition in different bacterial strains exposed to tetrahexylammonium bromide ionic liquid (THAB_IL). (A) Gram-positive bacteria, (B) Gram-negative bacteria. The tested tetrahexylammonium bromide (THAB_IL) concentrations were: c1, 13.6 mg/ml; c2, 6.8 mg/ml; c3, 3.4 mg/ml; c4, 1.7 mg/ml; and c5, 0.85 mg/ml. Gn-gentamicin; Sxt-trimethoprim/sulfamethoxazole (*P<0.1, **P<0.01, ***P<0.001).
Figure 2The rate of inhibition (%) for bacterial strains exposed to tetrahexylammonium bromide ionic liquid (THAB_IL). (A) Gram-positive bacteria, (B) Gram-negative bacteria. The tested tetrahexylammonium bromide (THAB_IL) concentrations were: c1, 13.6 mg/ml; c2, 6.8 mg/ml; c3, 3.4 mg/ml; c4, 1.7 mg/ml; and c5, 0.85 mg/ml. Gn-gentamicin; Sxt-trimethoprim/sulfamethoxazole).
Figure 3Caco-2 cell (2D cell culture) inhibition rate after tetrahexylammonium bromide ionic liquid (THAB_IL) treatment at different concentrations for 24, 48 and 72 h. One-way ANOVA analysis followed by Dunnett's multiple comparisons post-test was utilized to detect the statistical differences between the control and the treated group (**P<0.01 and ****P<0.0001).
Figure 4Caco-2 cell (3D cell culture) inhibition rate after tetrahexylammonium bromide ionic liquid (THAB_IL) treatment at different concentrations. One-way ANOVA analysis followed by Dunnett's multiple comparisons post-test was utilized to detect the statistical differences between the control and the treated group (****P<0.0001).
Figure 5Mature cellular aggregate morphology of the different treatment groups. Control, Caco-2 cells seeded in a 3D plate; THABr_IL 10 mM, Caco-2 cells seeded in a 3D plate and treated with 10 mM tetrahexylammonium bromide ionic liquid; THABr_IL 5 mM, Caco-2 cells seeded in 3D plate and treated with 5 mM tetrahexylammonium bromide ionic liquid; THABr_IL 2.5 mM, Caco-2 cells seeded in 3D plate and treated with 2.5 mM tetrahexylammonium bromide ionic liquid; THABr_IL 0.1 mM, Caco-2 cells seeded in a 3D plate and treated with 0.1 mM tetrahexylammonium bromide ionic liquid. Scale bar, 100 µm.